Zai Lab Announces Participation in January Investor Conferences

Rhea-AI Summary

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in key investor conferences in January 2023. The company will be present at the Morgan Stanley Virtual China Opportunity Conference from January 4-6, and will present at the J.P. Morgan 41st Annual Healthcare Conference on January 10 at 9:00 a.m. PST in San Francisco. The webcast for the J.P. Morgan conference will be accessible on Zai Lab’s Investor Relations site, with an archived replay available for 30 days. Zai Lab focuses on developing transformative medicines in oncology, autoimmune disorders, infectious diseases, and neurological disorders.

Positive

• Participation in prestigious investor conferences enhances visibility and engagement with investors.
• Focus on innovative treatments in high-demand therapeutic areas could fuel future growth.

Negative

• None.

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that senior management from Zai Lab will participate in the following investor conferences in January 2023:

Morgan Stanley Virtual China Opportunity Conference
Meetings: Wednesday, January 4, 2023 - Friday, January 6, 2023

J.P. Morgan 41st Annual Healthcare Conference
Presentation: Tuesday, January 10, 2023, 9:00 a.m. PST
Location: San Francisco

Webcast link of the corporate presentation at the J.P. Morgan 41st Annual Healthcare Conference will be available under “Events & Presentations” in the Investor Relations section of Zai Lab’s website. The archived replay will be viewable after the events for 30 days.

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com and follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

Investor Relations: Lina Zhang
+86 136 8257 6943
lina.zhang@zailaboratory.com

Media: Christine Drury / Xiaoyu Chen
+1 (317) 385-9227 / +86 185 0015 5011
christine.drury@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited

FAQ

What conferences will Zai Lab participate in January 2023?

Zai Lab will participate in the Morgan Stanley Virtual China Opportunity Conference from January 4-6 and the J.P. Morgan 41st Annual Healthcare Conference on January 10.

What is Zai Lab's focus as a biopharmaceutical company?

Zai Lab focuses on developing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.

Where can I watch Zai Lab's presentation at the J.P. Morgan conference?

The webcast for Zai Lab's presentation at the J.P. Morgan conference will be available on their Investor Relations website.

How long will the J.P. Morgan conference replay be available?

The archived replay of Zai Lab's presentation at the J.P. Morgan conference will be available for 30 days.